Milind A. Phadnis, MS, PhD

Professional Background

Milind Phadnis is an Associate Professor in Department of Biostatistics & Data Science at the University of Kansas Medical Center. His methodological interests are in the field of Survival Analysis and Design of Clinical Trials. He has collaborated extensively with researchers from nephrology, stroke, neurology, oncology and many other areas. He is the co-director of the Biostatistics section of Investigator Initiated Trials supported by the Cancer Center at his university. He has also served as the site-PI for an American Heart Association grant and is a two-time winner of Biostatistics & Epidemiology Research Design award at his university. He teaches Masters and PhD level courses in Biostatistics to students in his department and also Service-level courses to students from other departments. He also won the Outstanding Graduate Teaching Award for the 2020-21 academic year.

• PhD, Biostatistics, University of Alabama-Birmingham, Birminbham, AL
• MS, Industrial Engineering, University of Alabama, Tuscaloosa, AL
• Other, Production Engineering, Fr. Conceicao Rodrigues College of Engineering, Mumbai, Maharashtra

• Association for Clinical and Translational Statisticians, Member, 2017 - Present
• Investigator Initiated Trials, Member, 2016 - Present
• University of Kansas Cancer Center, Member, 2015 - Present
• American Statistical Association, Member, 2010 - Present

---

• Wetmore, James., B, Phadnis, Milind., A, Mahnken, Jonathan., D, Ellerbeck, Edward., F, Rigler, Sally., K, Zhou, Xinhua, Shireman, Theresa., I. 2014. Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients.. Clinical Journal of the American Society of Nephrology, 9 (4), 756-763. https://cjasn.asnjournals.org/content/clinjasn/9/4/756.full.pdf
• Phadnis, Milind., A, Wetmore, James., B, Mayo, Matthew., S. 2017. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.. Statistics in Medicine, 36, 4121-4140. https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.7421
• Phadnis, Milind., A, Wetmore, James., B, Shireman, Theresa., I, Ellerbeck, Edward., F, Mahnken, Jonathan., D. 2017. An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population.. Statistical Methods in Medical Research, 26 (6), 2667-2680. https://journals.sagepub.com/doi/pdf/10.1177/0962280215605107
• Phadnis, Milind., A, Mayo, Matthew., S. 2021. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.. Biometrical journal, 63 (7), 1406-1433. https://doi.org/10.1002/bimj.202000043
• Sharma, Priyanka, Abramson, Vandana., G, O'Dea, Anne, Nye, Lauren, Mayer, Ingrid, Pathak, Harsh., B, Hoffmann, Marc, Stecklein, Shane., R, Elia, Manana, Lewis, Sharon, Scott, Jecinta, De Jong, Jilliann., A, Wang, Yen., Y, Yoder, Rachel, Schwensen, Kelsey, Finke, Karissa, Heldstab, Jaimie, LaFaver, Stephanie, Williamson, Stephen., K, Phadnis, Milind., A, Reed, Gregory., A, Kimler, Bruce., F, Khan, Qamar., J, Godwin, Andrew., K. 2021. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.. Clinical Cancer Research, 27 (14), 3896-3904. https://doi.org/10.1158/1078-0432.ccr-20-4879
• Waleed, Muhammad, He, Jianghua, Phadnis, Milind., A. 2021. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.. Pharmaceutical Statistics, 20 (3), 610-644. https://dx.doi.org/10.1002/pst.2097
• Jain, Nishank, Phadnis, Milind., A, Hunt, Suzanne., L, Dai, Junqiang, Shireman, Theresa., I, Davis, Clayton., L, Mehta, Jawahar., L, Rasu, Rafia., S, Hedayati, S., Susan. 2021. Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis.. Kidney International Reports, 6 (9), 2381-2391. https://doi.org/10.1016/j.ekir.2021.06.031
• Saeed, Anwaar, Park, Robin, Dai, Junqiang, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Saeed, Azhar, Ripp, Jacob, Collins, Zachary, Mulvaney, Kelly, Shugrue, Molly, Firth-Braun, Jeanette, Godwin, Andrew., K, Madan, Rashna, Phadnis, Milind, Sun, Weijing. 2023. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Reports Medicine, 4 (2), 1-11. https://doi.org/10.1016/j.xcrm.2023.100916
• Sun, Weijing, Veeramachaneni, Nirmal, Al-Rajabi, Raed, Madan, Rashna, Kasi, Anup, Al-Kasspooles, Mazin, Baranda, Joaquina, Saeed, Anwaar, Phadnis, Milind., A, Godwin, Andrew., K, Olyaee, Mojtaba, Streeter, Natalie, Nagji, Alykhan, Dai, Junqiang, Williamson, Stephen . 2023. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma. Cancer Medicine, 12 (15), 16098-16107. https://pubmed.ncbi.nlm.nih.gov/37326317/
• Waleed, Muhammed, He, Jianghua, Phadnis, Milind., A. 2023. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter. Journal of Biopharmaceutical Statistics, 34 (4), 469-487. https://doi.org/10.1080/10543406.2023.2234998